PMID- 22872931
OWN - NLM
STAT- MEDLINE
DCOM- 20120828
LR  - 20120809
IS  - 0967-4845 (Print)
IS  - 0967-4845 (Linking)
VI  - 69
IP  - 2
DP  - 2012
TI  - Quantification of tumour and circulating vascular endothelial growth factor 
      (VEGF) in patients with oesophagogastric cancer: a long-term follow-up study.
PG  - 71-5
AB  - Vascular endothelial growth factor (VEGF) is an angiogenic cytokine that 
      regulates tumour angiogenesis. The prognostic significance of VEGF expression 
      remains incompletely investigated for patients with oesophagogastric cancer. This 
      study assesses the significance of tumour VEGF (T-VEGF) and circulating VEGF 
      (C-VEGF) expression in a 10-year follow-up of patients with oesophagogastric 
      cancer. Patients undergoing surgical resection were prospectively recruited 
      between February 1999 and August 2000. Circulating VEGF, derived both from plasma 
      (P-VEGF) and serum (S-VEGF), and T-VEGF were assessed using a commercial 
      enzyme-linked immunosorbent assay (ELISA). As platelet count may contribute to 
      C-VEGF, pre-operative platelet levels were also recorded to exclude a confounding 
      effect. Patients were followed up over a 10-year period using the Northern 
      Ireland Cancer Registry. Sixty-one patients were recruited (men=45) with a mean 
      age of 65.7 years. The 10-year survival was 19.7% (n=12) with a median follow-up 
      of 808 days (inter-quartile range [IQR]: 349.5-2358.5). Union for International 
      Cancer Control (UICC) tumour staging was Stage I=9 (14.8%), Stage II=15 (24.6%), 
      Stage III=33 (54.1%) and Stage IV=4 (6.6%). The only significant relationship 
      between clinicopathological features and the study variables was for S-VEGF, 
      which was elevated in patients with advanced T-stage (P = 0.05). Circulating VEGF 
      did not correlate with platelet count. Although a trend towards decreased 
      survival was observed for patients who had positive lymph nodes (P = 0.08) and 
      advanced UICC stage (P = 0.09) on univariate analysis, only lymphovascular 
      invasion significantly predicted poor prognosis in this cohort (P = 0.05). 
      Therefore, ELISA quantification of circulatory or tumour VEGF does not appear to 
      be a significant predictor of mortality in patients with oesophagogastric cancer.
FAU - Gray, R T
AU  - Gray RT
AD  - Department of Upper Gastrointestinal Surgery, Ulster Hospital, Northern Ireland, 
      UK. rgray05@qub.ac.uk
FAU - O'Donnell, M E
AU  - O'Donnell ME
FAU - McGuigan, J A
AU  - McGuigan JA
FAU - Spence, G M
AU  - Spence GM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Br J Biomed Sci
JT  - British journal of biomedical science
JID - 9309208
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Squamous Cell/*blood
MH  - Enzyme-Linked Immunosorbent Assay/methods
MH  - Esophageal Neoplasms/*blood
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neovascularization, Pathologic
MH  - Platelet Count
MH  - Prognosis
MH  - Stomach Neoplasms/*genetics
MH  - Vascular Endothelial Growth Factor A/*biosynthesis
EDAT- 2012/08/10 06:00
MHDA- 2012/08/29 06:00
CRDT- 2012/08/10 06:00
PHST- 2012/08/10 06:00 [entrez]
PHST- 2012/08/10 06:00 [pubmed]
PHST- 2012/08/29 06:00 [medline]
PST - ppublish
SO  - Br J Biomed Sci. 2012;69(2):71-5.